PAG
AKBA icon

Private Advisor Group’s Akebia Therapeutics AKBA Stock Holding History

Private Advisor Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-61,816
Closed -$119K – 2480
2025
Q1 		$119K Hold
61,816
– – ﹤0.01% 2179
2024
Q4 		$117K Buy
61,816
+3,000
+5% +$5.21K ﹤0.01% 2160
2024
Q3 		$77.6K Sell
58,816
-810
-1% -$1.08K ﹤0.01% 2330
2024
Q2 		$60.8K Buy
+59,626
New +$73.7K ﹤0.01% 2262
2024
Q1 		– Sell
-20,235
Closed -$25.1K – 2324
2023
Q4 		$25.1K Buy
20,235
+4,094
+25% +$4.18K ﹤0.01% 2184
2023
Q3 		$18.4K Buy
+16,141
New +$20.7K ﹤0.01% 2118
2022
Q3 		– Sell
-20,316
Closed -$7K – 1914
2022
Q2 		$7K Buy
+20,316
New +$8.53K ﹤0.01% 2098
2020
Q3 		– Sell
-1,860
Closed -$25K – 1611
2020
Q2 		$25K Buy
+1,860
New +$19.2K ﹤0.01% 2453

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Private Advisor Group's AKBA Position: Q2 2025 in Review

Private Advisor Group sold out of Akebia Therapeutics (AKBA) in Q2 2025, closing a stake of 61,816 shares — an estimated $119K sold.

Private Advisor Group first reported a position in AKBA in Q2 2020 and held it in 8 quarters. The position peaked at $119K in Q1 2025. 157 funds tracked by Wall St. Rank hold AKBA as of Q2 2025.

  • Private Advisor Group reported no remaining Akebia Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Private Advisor Group sold 61,816 Akebia Therapeutics shares in Q2 2025, an estimated $119K.
  • Private Advisor Group first reported a position in Akebia Therapeutics in Q2 2020 and held it in 8 quarters.
  • Private Advisor Group's Akebia Therapeutics position peaked at $119K in Q1 2025.
  • 157 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2025.

Based on Private Advisor Group's 13F filing for Q2 2025, filed 11 Aug 2025.